Pharmaceutical Business review

Acucela, Otsuka commence OPA-6566 Phase 1/2 trial

Discovered by Otsuka, OPA-6566 is an ophthalmic solution indicated to reduce intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension patients

The trial aims to evaluate the safety, tolerability and the IOP-lowering effects of OPA-6566 in patients with open-angle glaucoma or ocular hypertension.

The trial will be conducted at clinical sites in the US.